Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,544
archived clinical trials in
Ovarian Cancer

Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
Phase 1, Open Label Study to Assess the Safety and Tolerability of U3 1565 in Subjects With Advanced Solid Malignant Tumors
Status: Enrolling
Updated:  4/24/2013
Sarah Cannon Research Institute
mi
from
Nashville, TN
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
Phase 1, Open Label Study to Assess the Safety and Tolerability of U3 1565 in Subjects With Advanced Solid Malignant Tumors
Status: Enrolling
Updated: 4/24/2013
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated:  6/25/2013
Clinical Research Facility
mi
from
Redlands, CA
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated: 6/25/2013
Clinical Research Facility
mi
from
Redlands, CA
Click here to add this to my saved trials
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated:  6/25/2013
Clinical Research Facility
mi
from
Mission Viejo, CA
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated: 6/25/2013
Clinical Research Facility
mi
from
Mission Viejo, CA
Click here to add this to my saved trials
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated:  6/25/2013
Clinical Research Facility
mi
from
Paducah, KY
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated: 6/25/2013
Clinical Research Facility
mi
from
Paducah, KY
Click here to add this to my saved trials
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated:  6/25/2013
Clinical Research Facility
mi
from
Covington, LA
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated: 6/25/2013
Clinical Research Facility
mi
from
Covington, LA
Click here to add this to my saved trials
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated:  6/25/2013
Clinical Research Facility
mi
from
Shreveport, LA
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated: 6/25/2013
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated:  6/25/2013
Clinical Research Facility
mi
from
Bozeman, MT
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated: 6/25/2013
Clinical Research Facility
mi
from
Bozeman, MT
Click here to add this to my saved trials
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated:  6/25/2013
Clinical Research Facility
mi
from
Cincinnati, OH
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated: 6/25/2013
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated:  6/25/2013
Clinical Research Facility
mi
from
Portland, OR
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated: 6/25/2013
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated:  6/25/2013
Clinical Research Facility
mi
from
San Antonio, TX
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated: 6/25/2013
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated:  6/25/2013
Clinical Research Facility
mi
from
Kennewick, WA
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated: 6/25/2013
Clinical Research Facility
mi
from
Kennewick, WA
Click here to add this to my saved trials
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated:  6/25/2013
Clinical Research Facility
mi
from
Mount Vernon, WA
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated: 6/25/2013
Clinical Research Facility
mi
from
Mount Vernon, WA
Click here to add this to my saved trials
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated:  6/25/2013
Clinical Research Facility
mi
from
Tacoma, WA
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated: 6/25/2013
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated:  6/25/2013
Clinical Research Facility
mi
from
Seattle, WA
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated: 6/25/2013
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated:  6/25/2013
Clinical Research Facility
mi
from
Tacoma, WA
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated: 6/25/2013
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated:  6/25/2013
Clinical Research Facility
mi
from
Wenatchee, WA
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Status: Enrolling
Updated: 6/25/2013
Clinical Research Facility
mi
from
Wenatchee, WA
Click here to add this to my saved trials
18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
A Pilot Study of [18F]-CP18 PET/CT Imaging in Patients With Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Therapy Receiving Birinapant, a SMAC Mimetic Therapy
Status: Enrolling
Updated:  7/2/2013
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
A Pilot Study of [18F]-CP18 PET/CT Imaging in Patients With Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Therapy Receiving Birinapant, a SMAC Mimetic Therapy
Status: Enrolling
Updated: 7/2/2013
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Stress Reduction for Overweight or Obese Women Either With Polycystic Ovary Syndrome (PCOS) or Without PCOS (Non-PCOS)
Stress Reduction for PCOS and Non-PCOS Women
Status: Enrolling
Updated:  9/7/2013
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Stress Reduction for Overweight or Obese Women Either With Polycystic Ovary Syndrome (PCOS) or Without PCOS (Non-PCOS)
Stress Reduction for PCOS and Non-PCOS Women
Status: Enrolling
Updated: 9/7/2013
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
The Effects Of Yoga On Quality Of Life Among A Population Of Ovarian/ Fallopian Tube/ Primary Peritoneal Cancer Patients Receiving Chemotherapy: A Feasibility Study
THE EFFECTS OF YOGA ON QUALITY OF LIFE AMONG A POPULATION OF OVARIAN/ FALLOPIAN TUBE/ PRIMARY PERITONEAL CANCER PATIENTS RECEIVING CHEMOTHERAPY: A FEASIBILITY STUDY
Status: Enrolling
Updated:  10/10/2013
Northwestern Memorial Hospital
mi
from
Chicago, IL
The Effects Of Yoga On Quality Of Life Among A Population Of Ovarian/ Fallopian Tube/ Primary Peritoneal Cancer Patients Receiving Chemotherapy: A Feasibility Study
THE EFFECTS OF YOGA ON QUALITY OF LIFE AMONG A POPULATION OF OVARIAN/ FALLOPIAN TUBE/ PRIMARY PERITONEAL CANCER PATIENTS RECEIVING CHEMOTHERAPY: A FEASIBILITY STUDY
Status: Enrolling
Updated: 10/10/2013
Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
New Biomarkers Evaluating Ovarian Cancer
Evaluation of New Biomarker Assays in Ovarian Cancer Patients Presenting to a Generalist With an Adnexal Mass
Status: Enrolling
Updated:  11/8/2013
New Hanover Regional Medical Center
mi
from
Wilmington, NC
New Biomarkers Evaluating Ovarian Cancer
Evaluation of New Biomarker Assays in Ovarian Cancer Patients Presenting to a Generalist With an Adnexal Mass
Status: Enrolling
Updated: 11/8/2013
New Hanover Regional Medical Center
mi
from
Wilmington, NC
Click here to add this to my saved trials
New Biomarkers Evaluating Ovarian Cancer
Evaluation of New Biomarker Assays in Ovarian Cancer Patients Presenting to a Generalist With an Adnexal Mass
Status: Enrolling
Updated:  11/8/2013
University of Oklahoma
mi
from
Oklahoma City, OK
New Biomarkers Evaluating Ovarian Cancer
Evaluation of New Biomarker Assays in Ovarian Cancer Patients Presenting to a Generalist With an Adnexal Mass
Status: Enrolling
Updated: 11/8/2013
University of Oklahoma
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
A Phase IV Study Comparing the Efficacy of Fosaprepitant to Aprepitant for Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecological Cancer
Status: Enrolling
Updated:  1/24/2014
Gynecologic Oncology Associates
mi
from
Newport Beach, CA
Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
A Phase IV Study Comparing the Efficacy of Fosaprepitant to Aprepitant for Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecological Cancer
Status: Enrolling
Updated: 1/24/2014
Gynecologic Oncology Associates
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated:  4/23/2014
Clinical Research Facility
mi
from
Stanford, CA
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated: 4/23/2014
Clinical Research Facility
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated:  4/23/2014
Clinical Research Facility
mi
from
Tampa, FL
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated: 4/23/2014
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated:  4/23/2014
Clinical Research Facility
mi
from
Saint Louis, MO
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated: 4/23/2014
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated:  4/23/2014
Clinical Research Facility
mi
from
New Brunswick, NJ
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated: 4/23/2014
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated:  4/23/2014
Clinical Research Facility
mi
from
Oklahoma City, OK
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated: 4/23/2014
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated:  4/23/2014
Clinical Research Facility
mi
from
Houston, TX
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated: 4/23/2014
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated:  4/23/2014
Clinical Research Facility
mi
from
Milwaukee, WI
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated: 4/23/2014
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Why do Oral Contraceptives Prevent of Ovarian Cancer?
Mechanisms of Prevention of Ovarian Cancer by Oral Contraceptives
Status: Enrolling
Updated:  6/2/2014
USC, Keck School of Medicine
mi
from
Los Angeles, CA
Why do Oral Contraceptives Prevent of Ovarian Cancer?
Mechanisms of Prevention of Ovarian Cancer by Oral Contraceptives
Status: Enrolling
Updated: 6/2/2014
USC, Keck School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
Roswell Park Cancer Institute
mi
from
Buffalo, NY
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
Scottsdale Healthcare
mi
from
Scottsdale, AZ
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
Scottsdale Healthcare
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  8/4/2014
University of Colorado Cancer Center
mi
from
Aurora, CO
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 8/4/2014
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  8/4/2014
University of Chicago Medical Center
mi
from
Chicago, IL
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 8/4/2014
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  8/4/2014
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 8/4/2014
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  8/4/2014
Dana Farber/Partners Cancer Care
mi
from
Boston, MA
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 8/4/2014
Dana Farber/Partners Cancer Care
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  8/4/2014
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 8/4/2014
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  8/4/2014
Princess Margaret Hospital
mi
from
Toronto,
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 8/4/2014
Princess Margaret Hospital
mi
from
Toronto,
Click here to add this to my saved trials
Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer
A Pilot Study of Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer
Status: Enrolling
Updated:  12/4/2014
University of Virginia
mi
from
Charlottesville, VA
Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer
A Pilot Study of Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer
Status: Enrolling
Updated: 12/4/2014
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Insulin Differences Between African-American and Caucasian Female Adolescents With Polycystic Ovary Syndrome (PCOS)
Differences in Insulin Secretion and Insulin Sensitivity/Resistance in African-American and Caucasian Adolescent Females With Polycystic Ovary Syndrome
Status: Enrolling
Updated:  2/2/2015
Clinical Research Center at The Ohio University Wexner Medical Center / Nationwide Children's Hospital
mi
from
Columbus, OH
Insulin Differences Between African-American and Caucasian Female Adolescents With Polycystic Ovary Syndrome (PCOS)
Differences in Insulin Secretion and Insulin Sensitivity/Resistance in African-American and Caucasian Adolescent Females With Polycystic Ovary Syndrome
Status: Enrolling
Updated: 2/2/2015
Clinical Research Center at The Ohio University Wexner Medical Center / Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer
A Randomized Controlled Pilot Trial of Vitamin D3 Replacement of Placebo Followed by Bilateral Salpingo-Oophorectomy for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer.
Status: Enrolling
Updated:  7/1/2015
Northwestern University
mi
from
Chicago, IL
Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer
A Randomized Controlled Pilot Trial of Vitamin D3 Replacement of Placebo Followed by Bilateral Salpingo-Oophorectomy for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer.
Status: Enrolling
Updated: 7/1/2015
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer
A Randomized Controlled Pilot Trial of Vitamin D3 Replacement of Placebo Followed by Bilateral Salpingo-Oophorectomy for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer.
Status: Enrolling
Updated:  7/1/2015
NorthShore University HealthSystem
mi
from
Evanston, IL
Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer
A Randomized Controlled Pilot Trial of Vitamin D3 Replacement of Placebo Followed by Bilateral Salpingo-Oophorectomy for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer.
Status: Enrolling
Updated: 7/1/2015
NorthShore University HealthSystem
mi
from
Evanston, IL
Click here to add this to my saved trials
Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)
Phase II Study of Bevacizumab and Doxil in the Treatment of Platinum-Resistant or Refractory Ovarian Cancer
Status: Enrolling
Updated:  7/6/2015
University of New Mexico
mi
from
Albuquerque, NM
Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)
Phase II Study of Bevacizumab and Doxil in the Treatment of Platinum-Resistant or Refractory Ovarian Cancer
Status: Enrolling
Updated: 7/6/2015
University of New Mexico
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)
Phase II Study of Bevacizumab and Doxil in the Treatment of Platinum-Resistant or Refractory Ovarian Cancer
Status: Enrolling
Updated:  7/6/2015
New Mexico Cancer Care Associates
mi
from
Santa Fe, NM
Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)
Phase II Study of Bevacizumab and Doxil in the Treatment of Platinum-Resistant or Refractory Ovarian Cancer
Status: Enrolling
Updated: 7/6/2015
New Mexico Cancer Care Associates
mi
from
Santa Fe, NM
Click here to add this to my saved trials
Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)
Phase II Study of Bevacizumab and Doxil in the Treatment of Platinum-Resistant or Refractory Ovarian Cancer
Status: Enrolling
Updated:  7/6/2015
New York University Cancer Institute
mi
from
New York City, NY
Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)
Phase II Study of Bevacizumab and Doxil in the Treatment of Platinum-Resistant or Refractory Ovarian Cancer
Status: Enrolling
Updated: 7/6/2015
New York University Cancer Institute
mi
from
New York City, NY
Click here to add this to my saved trials
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours
Status: Enrolling
Updated:  7/7/2015
Gynecologic Oncology Associates
mi
from
Newport Beach, CA
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours
Status: Enrolling
Updated: 7/7/2015
Gynecologic Oncology Associates
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours
Status: Enrolling
Updated:  7/7/2015
Research Facility
mi
from
Orlando, FL
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours
Status: Enrolling
Updated: 7/7/2015
Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours
Status: Enrolling
Updated:  7/7/2015
Hematology and Oncology Specialists, LLC
mi
from
Covington, LA
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours
Status: Enrolling
Updated: 7/7/2015
Hematology and Oncology Specialists, LLC
mi
from
Covington, LA
Click here to add this to my saved trials